Since modulating LRP6 and GSK3β expression levels is sufficient to alter the status of insulin sensitivity in hepatocytes, altering LRP6 and GSK3β expression may represent a potential therapeutic strategy for insulin resistance associated metabolism disorders. This evidence concerns the gene GSK3B and Other metabolic disease.